Last reviewed · How we verify
Calcium Gluconate (CALCIUM GLUCONATE)
Calcium gluconate increases serum ionized calcium levels when administered intravenously.
Calcium Gluconate is a small molecule calcium salt used to treat hypocalcemia, hypocalcemic tetany, and osteoporosis. It is a generic medication, with multiple manufacturers, and is currently owned by Fresenius Kabi USA. The exact mechanism of action is not well-documented, but it is believed to work by replenishing calcium stores in the body. Calcium Gluconate is not a patented medication, indicating it is no longer under exclusive patent protection. Key safety considerations include potential cardiac complications and interactions with other medications.
At a glance
| Generic name | CALCIUM GLUCONATE |
|---|---|
| Sponsor | Fresenius Kabi Usa |
| Drug class | calcium gluconate |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
| First approval | 2017 |
Mechanism of action
When calcium gluconate is given intravenously, it dissociates into ionized calcium in the plasma. This increase in ionized calcium levels can affect various physiological processes that depend on calcium.
Approved indications
- Hypocalcemia
- Hypocalcemic tetany
- Osteoporosis
Common side effects
- local soft tissue inflammation
- necrosis
- calcification
- vasodilation
- decreased blood pressure
- bradycardia
- cardiac arrhythmia
- syncope
- cardiac arrest
- calcinosis cutis
Key clinical trials
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- Effect of 1% Melatonin Gel Versus Calcium Hydroxide as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp. (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- Clinical Evaluation of an Experimental Remineralization Product (NA)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 10342813 | 2037-07-25 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium Gluconate CI brief — competitive landscape report
- Calcium Gluconate updates RSS · CI watch RSS